CUREVAC N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.665 USD | +0.57% |
|
-11.95% | -37.89% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people's lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.492
EUR
Average target price
11.39
EUR
Spread / Average Target
+357.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.89% | 593M | |
| +48.04% | 42.16B | |
| -0.83% | 42.07B | |
| +3.46% | 39.77B | |
| -11.36% | 26.68B | |
| +4.40% | 24.68B | |
| -23.45% | 18.68B | |
| -1.30% | 12.11B | |
| +26.38% | 11.99B | |
| +6.37% | 11.06B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- Market Chatter: German Financial Watchdog to Investigate Possible Insider Trading at CureVac
